Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Cytek Biosciences (Nasdaq: CTKB) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026. Management will take part in a hybrid presentation and fireside chat at 8:10 a.m. PT / 11:10 a.m. ET.
According to the company, a live and archived webcast will be available via the Investors section at investors.cytekbio.com.
Positive
- None.
Negative
- None.
News Market Reaction – CTKB
In the Feb 19 session, CTKB gained 3.33%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.1% during that session.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings date notice | Neutral | -4.4% | Announced timing for Q4 and full-year 2025 financial results. |
| Jan 12 | Prelim revenue update | Positive | +6.4% | Shared preliminary Q4 and full-year 2025 revenue growth figures. |
| Nov 12 | Growth recognition | Positive | +0.4% | Named to TIME’s 2026 America’s Growth Leaders list for performance. |
| Nov 06 | Product award | Positive | +1.8% | Muse Micro cell analyzer won Drug Discovery Solution of the Year award. |
| Nov 06 | Investor conferences | Neutral | +1.8% | Outlined multiple upcoming healthcare investor conference appearances. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news tied to operations, awards, and conferences often saw positive moves (4 of 5 events up), while an earnings date announcement on Feb 12, 2026 coincided with a -4.36% decline.
Over the past several months, Cytek reported preliminary Q4 2025 and full-year revenue on Jan 12, 2026, which was followed by a +6.42% move, and announced upcoming full results on Feb 26, 2026, with shares down 4.36% afterward. Earlier, the company received industry recognition from TIME and a BioTech Breakthrough award, and detailed multiple investor conference appearances in late 2025. Today’s TD Cowen conference participation continues this pattern of regular investor and industry engagement updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
Cytek management is scheduled to participate in a hybrid presentation and fireside chat on Wednesday, March 4th at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
